<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01247363</url>
  </required_header>
  <id_info>
    <org_study_id>14130</org_study_id>
    <secondary_id>I3P-FW-GKBE</secondary_id>
    <nct_id>NCT01247363</nct_id>
  </id_info>
  <brief_title>A Study of LY2608204 in Patients With Type 2 Diabetes</brief_title>
  <official_title>Safety and Tolerability of Multiple Ascending Doses of LY2608204 in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety study with multiple oral doses of LY2608204 given to patients with type 2 diabetes.
      Study subjects will receive once daily doses of LY2608204 for a total treatment duration of
      up to 28 days. In this study, each patient will receive increasing doses of LY2608204 until
      reaching the highest dose that they can tolerate.

      Continuous glucose monitoring devices will be employed for each patient to monitor for
      hypoglycemia during study treatment. Dose titration and dose reduction is determined for each
      individual patient based on their safety and glycemic data.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Adverse Effects</measure>
    <time_frame>Day 1 through Day 49</time_frame>
    <description>Clinically significant adverse effects refer to any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the investigational product, whether or not related to the medicinal investigational product.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve (AUC)</measure>
    <time_frame>Predose, 1, 2, 4, 6, 7, 10, 12 and 24 hours Postdose</time_frame>
    <description>AUC for Day 1 is AUC from 0 to 24 hours. AUC for all other days is AUC at a dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Drug Concentration (Cmax)</measure>
    <time_frame>Predose, 1, 2, 4, 6, 7, 10, 12, 24, 48, 120 and 168 hours Postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Drug Concentration (Tmax)</measure>
    <time_frame>Predose, 1, 2, 4, 6, 7, 10, 12, 24, 48, 120 and 168 hours Postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hypoglycemic Events</measure>
    <time_frame>Day 1 through Day 29</time_frame>
    <description>Number of hypoglycemia events with blood glucose concentration &lt;70 milligram/deciliter (mg/dL).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>LY2608204</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral capsules of LY2608204 given once daily at a starting dose of 160 milligram (mg), which may be titrated in 3 dose escalations to 240 mg, 320 mg and 400 mg, with a 7-day treatment duration at each dose level for up to 28 days total treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2608204</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY2608204</arm_group_label>
    <other_name>Glucokinase Activator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with Type 2 diabetes mellitus (T2DM) who are currently treated with
             diet/lifestyle measures alone or in combination with anti-diabetic agents, including
             insulins

          -  Have fasting blood glucose (FBG) greater than or equal to 160 milligram/deciliter
             (mg/dL), with a subset of patients with FBG greater than or equal to 190 mg/dL in at
             least 2 measurements on separate days

          -  Have a glycated haemoglobin (HbA1c) level of greater than or equal to 8% and less than
             or equal to 11% at screening

          -  If female, are not of child-bearing potential due to surgical sterilisation
             (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause

          -  Are males or females who are at least 18 years old (for sites outside of Singapore) or
             at least 21 years old (for sites within Singapore) but no more than 70 years old (for
             all sites)

          -  Body mass index (BMI) greater than 18.5 kilogram/square meter (kg/m²) and less than
             40.0 kg/m²

          -  Have clinical laboratory test results within the normal range for the population or
             investigator site, or with abnormalities deemed clinically insignificant by the
             investigator

          -  Have supine systolic blood pressure (SBP) greater than 160 millimeters of mercury
             (mmHg) and supine diastolic blood pressure (DBP) less than 100 mmHg

          -  Have venous access sufficient to allow blood sampling as per the protocol

          -  Are willing and able to comply with requirements for continuous glucose monitoring
             (CGM)

          -  Are reliable and willing to make themselves available for the duration of the study
             and who will abide by the Clinical Research Unit (CRU) policy and procedure and study
             restrictions. This includes staying in-patient at the CRU for a total duration of up
             to 31 days

          -  Have given written informed consent approved by Lilly and the ethical review board
             governing the site

        Exclusion Criteria:

          -  Are currently enrolled in, or discontinued within the last 30 days from, a clinical
             trial involving an investigational drug or device or use of a drug or device other
             than the study drug used in this study, or are concurrently enrolled in any other type
             of medical research judged not to be scientifically or medically compatible with this
             study

          -  Have significant history of past or current cardiovascular, respiratory, hepatic,
             renal, gastrointestinal, endocrine (other than diabetes), hematological, or
             neurological disorders capable of significantly altering the absorption, metabolism or
             elimination of drugs or of constituting a risk when taking the study drug formulations
             or interfering with the interpretation of data

          -  Have a history of a seizure disorder

          -  A corrected QT interval greater than 450 milliseconds (msec) at screening or any
             personal history of ventricular tachycardia or unexplained syncope, or other
             abnormality in the 12-lead Electrocardiogram (ECG) that, in the opinion of the
             investigator, increases the risks associated with participating in the study

          -  Have family history of long QT syndrome or family history of sudden unexplained death

          -  Use medications known to prolong the QT interval.

          -  Have type 1 diabetes mellitus or a history of ketoacidosis or any other type of
             diabetes mellitus other than type 2

          -  Use of any known inducers or inhibitors of CYP3A within 14 days prior to the first
             dosing with study drug or intended use during the study

          -  History of a hypoglycemic event with acute mental status alteration that was not
             preceded by prodromal symptoms recognizable to the patient

          -  Fasting serum triglycerides greater than 500mg/dl

          -  Serum creatinine greater than 1.3 mg/dL in women, greater than 1.5 mg/dL in men

          -  Clinical evidence of active diabetic proliferative retinopathy

          -  Known clinically significant autonomic neuropathy as evidenced by urinary retention,
             orthostatic hypotension, diabetic diarrhea or gastroparesis

          -  Clinically significant coronary events or symptoms within 6 months prior to study
             entry

          -  Clinically significant peripheral vascular disease

          -  Have known allergies to LY2608204 or related compounds

          -  Evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV
             antibodies/antigen

          -  Evidence of hepatitis B and/or positive hepatitis B surface antigen (HBsAg)

          -  Donation or loss of blood equal to or exceeding 450 milliliter (mL) during the 3
             months before the first administration of study drug

          -  Patients who have an average weekly alcohol intake that exceeds 21 units per week
             (males) and 14 units per week (females) (1 unit equal to 12 oz or 360 mL of beer; 5 oz
             or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits) or patients unwilling to stop
             alcohol consumption 24 hours prior to admission until the completion of each
             in-patient study period

          -  Patients who smoke more than 10 cigarettes or other tobacco products per day before
             study entry. Patients will not be allowed to smoke while in the study Unit

          -  Have a history of drug or alcohol abuse

          -  Intended use of over-the counter or prescription medications 7 and 14 days,
             respectively, prior to dosing. If this situation arises, inclusion of an otherwise
             suitable volunteer may be at the discretion of the investigator. Use of anti-diabetic
             medication [metformin, sulphonylureas, glinides, thiazolidinediones, acarbose, DPPIV
             inhibitors, Byetta (but not liraglutide)] by patients with type 2 diabetes mellitus is
             acceptable for this study

          -  Have repeated alanine transaminase levels greater than 2.5 times the upper limit of
             the reference range at screening, as determined by the central laboratory

          -  Have previously been enrolled in this clinical study or any other study of LY2608204.

        Exclusion Criteria for EU/UK/US Site(s) only --

          -  Evidence of hepatitis C and/or positive hepatitis C antibodies, at screening

          -  Use of known drugs of abuse and/or positive findings on urinary drug screening, other
             than findings consistent with medication prescribed by the patient's physician or
             over-the-counter medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <zip>117597</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>November 22, 2010</study_first_submitted>
  <study_first_submitted_qc>November 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2010</study_first_posted>
  <results_first_submitted>February 17, 2018</results_first_submitted>
  <results_first_submitted_qc>February 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 3, 2018</results_first_posted>
  <last_update_submitted>October 18, 2018</last_update_submitted>
  <last_update_submitted_qc>October 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes glucokinase safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LY2608204</title>
          <description>Oral capsules of LY2608204 given once daily at a starting dose of 160 mg, which was titrated in 3 dose escalations to 240 mg, 320 mg and 400 mg, with a 7-day treatment duration at each dose level for up to 28 days total treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LY2608204</title>
          <description>Oral capsules of LY2608204 given once daily at a starting dose of 160 mg, which was titrated in 3 dose escalations to 240 mg, 320 mg and 400 mg, with a 7-day treatment duration at each dose level for up to 28 days total treatment.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.4" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Blood Glucose (FBG)</title>
          <units>milligram/deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="233.5" spread="38.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycated Hemoglobin (HbA1c)</title>
          <description>HbA1c is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time.</description>
          <units>percentage of glycated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.48" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Adverse Effects</title>
        <description>Clinically significant adverse effects refer to any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the investigational product, whether or not related to the medicinal investigational product.</description>
        <time_frame>Day 1 through Day 49</time_frame>
        <population>Participants who were administered study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>160 mg LY2608204</title>
            <description>Oral capsules of LY2608204 given once daily at dose of 160 milligram (mg)</description>
          </group>
          <group group_id="O2">
            <title>240 mg LY2608204</title>
            <description>Oral capsules of LY2608204 given once daily at dose of 240 mg</description>
          </group>
          <group group_id="O3">
            <title>320 mg LY2608204</title>
            <description>Oral capsules of LY2608204 given once daily at dose of 320 mg</description>
          </group>
          <group group_id="O4">
            <title>400 mg LY2608204</title>
            <description>Oral capsules of LY2608204 given once daily at dose of 400 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Adverse Effects</title>
          <description>Clinically significant adverse effects refer to any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the investigational product, whether or not related to the medicinal investigational product.</description>
          <population>Participants who were administered study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Time Curve (AUC)</title>
        <description>AUC for Day 1 is AUC from 0 to 24 hours. AUC for all other days is AUC at a dosing interval.</description>
        <time_frame>Predose, 1, 2, 4, 6, 7, 10, 12 and 24 hours Postdose</time_frame>
        <population>Participants who were administered study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>160 mg LY2608204 Day 1</title>
            <description>Oral capsules of LY2608204 given once at dose of 160 milligram (mg)</description>
          </group>
          <group group_id="O2">
            <title>160 mg LY2608204 Day 7</title>
            <description>Oral capsules of LY2608204 given once daily at dose of 160 mg</description>
          </group>
          <group group_id="O3">
            <title>240 mg LY2608204 Day 14</title>
            <description>Oral capsules of LY2608204 given once daily at dose of 240 mg</description>
          </group>
          <group group_id="O4">
            <title>320 mg LY2608204 Day 21</title>
            <description>Oral capsules of LY2608204 given once daily at dose of 320 mg</description>
          </group>
          <group group_id="O5">
            <title>400 mg LY2608204 Day 28</title>
            <description>Oral capsules of LY2608204 given once daily at dose of 400 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time Curve (AUC)</title>
          <description>AUC for Day 1 is AUC from 0 to 24 hours. AUC for all other days is AUC at a dosing interval.</description>
          <population>Participants who were administered study drug.</population>
          <units>nanogram.hour/milliliter (ng.hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1090" spread="30"/>
                    <measurement group_id="O2" value="2780" spread="30"/>
                    <measurement group_id="O3" value="5450" spread="30"/>
                    <measurement group_id="O4" value="8650" spread="28"/>
                    <measurement group_id="O5" value="12100" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Drug Concentration (Cmax)</title>
        <time_frame>Predose, 1, 2, 4, 6, 7, 10, 12, 24, 48, 120 and 168 hours Postdose</time_frame>
        <population>Participants who were administered study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>160 mg LY2608204 Day 1</title>
            <description>Oral capsules of LY2608204 given once at dose of 160 milligram (mg)</description>
          </group>
          <group group_id="O2">
            <title>160 mg LY2608204 Day 7</title>
            <description>Oral capsules of LY2608204 given once daily at dose of 160 mg</description>
          </group>
          <group group_id="O3">
            <title>240 mg LY2608204 Day 14</title>
            <description>Oral capsules of LY2608204 given once daily at dose of 240 mg</description>
          </group>
          <group group_id="O4">
            <title>320 mg LY2608204 Day 21</title>
            <description>Oral capsules of LY2608204 given once daily at dose of 320 mg</description>
          </group>
          <group group_id="O5">
            <title>400 mg LY2608204 Day 28</title>
            <description>Oral capsules of LY2608204 given once daily at dose of 400 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Drug Concentration (Cmax)</title>
          <population>Participants who were administered study drug.</population>
          <units>nanogram/milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.7" spread="33"/>
                    <measurement group_id="O2" value="175" spread="31"/>
                    <measurement group_id="O3" value="336" spread="32"/>
                    <measurement group_id="O4" value="515" spread="30"/>
                    <measurement group_id="O5" value="690" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Drug Concentration (Tmax)</title>
        <time_frame>Predose, 1, 2, 4, 6, 7, 10, 12, 24, 48, 120 and 168 hours Postdose</time_frame>
        <population>Participants who were administered study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>160 mg LY2608204 Day 1</title>
            <description>Oral capsules of LY2608204 given once at dose of 160 milligram (mg)</description>
          </group>
          <group group_id="O2">
            <title>160 mg LY2608204 Day 7</title>
            <description>Oral capsules of LY2608204 given once daily at dose of 160 mg</description>
          </group>
          <group group_id="O3">
            <title>240 mg LY2608204 Day 14</title>
            <description>Oral capsules of LY2608204 given once daily at dose of 240 mg</description>
          </group>
          <group group_id="O4">
            <title>320 mg LY2608204 Day 21</title>
            <description>Oral capsules of LY2608204 given once daily at dose of 320 mg</description>
          </group>
          <group group_id="O5">
            <title>400 mg LY2608204 Day 28</title>
            <description>Oral capsules of LY2608204 given once daily at dose of 400 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Drug Concentration (Tmax)</title>
          <population>Participants who were administered study drug.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.50" lower_limit="4.00" upper_limit="12.00"/>
                    <measurement group_id="O2" value="6.50" lower_limit="2.00" upper_limit="12.00"/>
                    <measurement group_id="O3" value="6.00" lower_limit="4.00" upper_limit="10.05"/>
                    <measurement group_id="O4" value="6.00" lower_limit="2.00" upper_limit="12.00"/>
                    <measurement group_id="O5" value="6.00" lower_limit="2.00" upper_limit="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hypoglycemic Events</title>
        <description>Number of hypoglycemia events with blood glucose concentration &lt;70 milligram/deciliter (mg/dL).</description>
        <time_frame>Day 1 through Day 29</time_frame>
        <population>Participants who were administered study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>160 mg LY2608204</title>
            <description>Oral capsules of LY2608204 given once daily at dose of 160 milligram (mg)</description>
          </group>
          <group group_id="O2">
            <title>240 mg LY2608204</title>
            <description>Oral capsules of LY2608204 given once daily at dose of 240 mg</description>
          </group>
          <group group_id="O3">
            <title>320 mg LY2608204</title>
            <description>Oral capsules of LY2608204 given once daily at dose of 320 mg</description>
          </group>
          <group group_id="O4">
            <title>400 mg LY2608204</title>
            <description>Oral capsules of LY2608204 given once daily at dose of 400 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hypoglycemic Events</title>
          <description>Number of hypoglycemia events with blood glucose concentration &lt;70 milligram/deciliter (mg/dL).</description>
          <population>Participants who were administered study drug.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>160 mg LY2608204</title>
          <description>Oral capsules of LY2608204 given once daily at dose of 160 milligram (mg)</description>
        </group>
        <group group_id="E2">
          <title>240 mg LY2608204</title>
          <description>Oral capsules of LY2608204 given once daily at dose of 240 mg</description>
        </group>
        <group group_id="E3">
          <title>320 mg LY2608204</title>
          <description>Oral capsules of LY2608204 given once daily at dose of 320 mg</description>
        </group>
        <group group_id="E4">
          <title>400 mg LY2608204</title>
          <description>Oral capsules of LY2608204 given once daily at dose of 400 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Procedural site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

